Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.62 |
| ▸ | PPARG | P37231 | 11/20 | 0.62 |
| ▸ | PPARA | Q07869 | 10/20 | 0.62 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219459 | 0.93 | PPARD (0.64) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10219630 | 0.91 | PPARD (0.64) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10219672 | 0.89 | PPARD (0.62) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10271124 | 0.88 | PPARG (0.47) | PPARDPPARGPPARANAAA | |
| SCHEMBL10219943 | 0.88 | PPARD (0.79) | PPARDPPARGPPARA | |
| SCHEMBL10220667 | 0.88 | PPARD (0.80) | PPARDPPARGPPARA | |
| SCHEMBL10219738 | 0.86 | PPARD (0.59) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10219945 | 0.86 | NPC1 (0.46) | PPARDPPARGPPARA | |
| SCHEMBL10219441 | 0.85 | PPARD (0.63) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10271106 | 0.85 | PPARD (0.60) | PPARDPPARGPPARAPCSK9DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.